By Rob Curran
Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease.
The Waltham, Mass., developer of biotech treatments for muscle diseases said its DYNE-101 product candidate, which is currently being tested in an early-stage Phase 1/2 clinical trial, received the fast-track designation, which the agency uses to expedite development of drugs for unmet needs. Dyne noted the fast-track status will make its drug eligible for a rolling review, enabling it to submit sections of the Biologic License Application for review as they are ready, rather than the company needing to complete all development steps before receiving input from the FDA.
Dyne anticipates filing for accelerated approval of the treatment in the first half of 2026.
"[Myotonic dystrophy type 1] is a devastating disease with no approved therapies," said Doug Kerr, chief medical officer of Dyne, in a statement.
Myotonic dystrophy is a genetic condition that causes muscle wasting and other debilitating symptoms.
Shares of Dyne was up 6.2% premarket.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 21, 2025 08:05 ET (13:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.